AZ: No plans for follow up on Brilinta-aspirin link

AstraZeneca doesn't plan to conduct a clinical trial to confirm that aspirin dosage caused a geographic discrepancy in the performance of its newly approved heart drug Brilinta. Some analysts had speculated such a trial might strengthen the image of the brand in the U.S., even though the company has not been asked to do so by regulators. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.